In the BioHarmony Drug Report Database

"Preview" Icon

Suvorexant

Belsomra (suvorexant) is a small molecule pharmaceutical. Suvorexant was first approved as Belsomra on 2014-08-13. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against orexin receptor type 1 and orexin receptor type 2. Belsomra’s patents are valid until 2033-05-29 (FDA).

 

Trade Name

 

Belsomra
 

Common Name

 

suvorexant
 

ChEMBL ID

 

CHEMBL1083659
 

Indication

 

sleep initiation and maintenance disorders
 

Drug Class

 

Orexin antagonist

Image (chem structure or protein)

Suvorexant structure rendering